BioSpace News Archive

Artesunate for Injection 110 mg, powder and solvent for solution is approved by FDA for initial treatment of severe malaria in adult and pediatric patients. Artesunate for Injection is in a group of drugs known as “artemisinin derivatives” and is on the World Health Organization Model List of Essential Medicines .

- First Quarter 2020 Revenues Increase 38% to $8.4 Million - - WatchPAT™ Revenues Increase 41% to $8.2 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, May 27, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, today report

ENZYMLOGIC S.L. (Enzymlogic) today announced that the European Patent Office has issued EU patent EP3350596B1 covering a novel method for determining kinetic profiles in drug discovery. This proprietary technology is applicable to the early stages of drug discovery, enabling key insight into important factors that influence efficacy, safety and new therapeutic opportunity. Enzymlogic has exclusive rights to the patented technology which underpins its KINETICfinder platform.

Report published by Trellis Rx identifies opportunities for mutually beneficial collaboration

Nucleus Biologics, a leader in precision cell culture, today announced the availability of NB-Lux™ , an online configuration and ordering platform for cell culture media. Designed for developers of cell therapies, NB-Lux™ speeds formulation development by providing real time pricing for cGMP grade media in lot sizes from two liters to 2000

The Institute for Functional Medicine announced Tracy W. Gaudet, MD, as the closing keynote speaker for IFM’s Annual International Conference 2020: Advancements in Clinical Research and Innovative Practices in Functional Medicine.

Central Admixture Pharmacy Services, Inc., the nation’s largest network of outsourcing admixture pharmacies, announced the expansion of its product portfolio.

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that the Company has filed for CE Mark for its Tiara TA Transapical mitral valve replacement system.

FARE calls on FDA urging prioritization of food allergies, requests collaboration across food allergy community, industry and FDA on strategy moving forward

Immunovia AB (publ) (“Immunovia”) today provides an update on the actions that the company is taking in response to the coronavirus (COVID-19) pandemic. During these challenging times, Immunovia remains focused on the sales start of the first-to-market test for early diagnosis of pancreatic cancer, IMMray™ PanCan-d.